DUBLIN–(BUSINESS WIRE)–The “Global
Metabolic Partnering 2014-2019: Deal Trends, Players and Financials”
report has been added to ResearchAndMarkets.com’s
offering.
Global Metabolic Partnering 2014 to 2019 provides the full collection of
Metabolic disease deals signed between the world’s pharmaceutical and
biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensors product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Metabolic disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering
Metabolic deals.
The report presents financial deal terms values for Metabolic deals,
where available listing by overall headline values, upfront payments,
milestones and royalties enabling readers to analyse and benchmark the
value of current deals.
The initial chapters of this report provide an orientation of
Metabolic dealmaking trends.
- Chapter 1 provides an introduction to the report.
-
Chapter 2 provides an overview of the trends in Metabolic dealmaking
since 2014 covering trends by year, deal type, stage of development,
technology type and therapeutic indication. -
Chapter 3 includes an analysis of financial deal terms covering
headline value, upfront payment, milestone payments and royalty rates. -
Chapter 4 provides a review of the leading Metabolic deals since 2014.
Deals are listed by headline value. The chapter includes the top 25
most active Metabolic dealmakers, together with a full listing of
deals to which they are a party. Where the deal has an agreement
contract published at the SEC a link provides online access to the
contract. -
Chapter 5 provides comprehensive access to Metabolic deals since 2014
where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities. Each
deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on
demand. -
Chapter 6 provides a comprehensive directory of all Metabolic
partnering deals by specific Metabolic target announced since 2014.
The chapter is organized by specific Metabolic therapeutic target.
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy
access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of
all Metabolic partnering deals signed and announced since 2014. The
appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing
easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in Metabolic partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Metabolic technologies and products.
Global Metabolic Partnering 2014 to 2019 includes:
- Trends in Metabolic dealmaking in the biopharma industry since 2014
- Analysis of Metabolic deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Metabolic deal contract documents
- Comprehensive access to over 750 Metabolic deal records
- The leading Metabolic deals by value since 2014
- Most active Metabolic dealmakers since 2014
The report includes deals for the following indications: Acromegaly,
Addison’s disease, Cirrhosis, Cushing’s syndrome, Diabetes, Type 1, Type
2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders,
Gynaecomastia, Inborn errors of metabolism, Phenylketonuria,
Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia,
Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease,
Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders,
Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary
cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate
Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic
indications.
Key Topics Covered:
1. Introduction
2. Trends in Metabolic dealmaking
2.1. Introduction
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication
3. Financial deal terms for Metabolic partnering
3.1. Introduction
3.2. Disclosed financials terms for Metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates
4. Leading Metabolic deals and dealmakers
4.1. Introduction
4.2. Most active in Metabolic partnering
4.3. List of most active dealmakers in Metabolic
4.4. Top Metabolic deals by value
5. Metabolic contract document directory
5.1. Introduction
5.2. Metabolic partnering deals where contract document available
6. Metabolic dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Metabolic therapeutic target
For more information about this report visit https://www.researchandmarkets.com/r/ytfgv9
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs